CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 114 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00337181
NCT00337181N/ACompleted
CompareCT.gov

Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E.

U.S. Army Medical Research and Development Command·observational·Posted Jun 15, 2006·Updated Aug 22, 2018

In Brief

An observational study for HIV-1. Completed, enrolled 114 participants across 1 site.

Detailed Summary

This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection in reference to study NCT00223080 RV144. The study will assess whether those who received the experimental vaccine combination have a slower progression of HIV disease compared to those who received the placebo injection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1
CountriesThailand
CollaboratorsWalter Reed Army Institute of Research (WRAIR), Royal Thai Ministry of Public Health, Mahidol University, Armed Forces Research Institute of Medical Sciences, Thailand, Sanofi Pasteur, a Sanofi Company

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 15, 2006
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.0 years ago